Bupropion as a modulator of drug activity
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
1. A method of treating major depressive disorder, comprising orally administering a combination of bupropion and dextromethorphan twice a day to a human being in need thereof for at least 8 consecutive days, wherein the combination comprises:
about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a bupropion in the free base form or another salt form; and
about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in the free base form or another salt form;
wherein the combination is orally administered in a single dosage form comprising the bupropion and the dextromethorphan as the only therapeutically active compounds, which provides immediate release of dextromethorphan and sustained release of bupropion; and
wherein the method is more effective in treating major depressive disorder than orally administering 105 mg of bupropion hydrochloride alone twice a day for at least 8 consecutive days.
2. The method of claim 1 , wherein the method is more effective in treating major depressive disorder than orally administering 45 mg of dextromethorphan hydrobromide alone twice a day for at least 8 consecutive days.
3. The method of claim 1 , wherein about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide are orally administered twice a day to the human being.
4. The method of claim 1 , wherein about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide are orally administered twice a day to the human being for at least 14 consecutive days.
5. The method of claim 1 , wherein about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide are orally administered twice a day to the human being for at least 30 consecutive days.
6. The method of claim 1 , wherein the combination is orally administered twice a day to the human being for at least 30 days.
7. A method of treating major depressive disorder, comprising orally administering a combination of bupropion and dextromethorphan once a day to a human being in need thereof for at least 8 consecutive days, wherein the combination comprises:
about 210 mg of bupropion hydrochloride, or a molar equivalent amount of bupropion in the free base form or another salt form; and
about 90 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in the free base form or another salt form;
wherein the combination is orally administered in a single dosage form comprising the bupropion and the dextromethorphan as the only therapeutically active compounds, which provides immediate release of dextromethorphan and sustained release of bupropion; and
wherein the method is more effective in treating major depressive disorder than orally administering 210 mg of bupropion hydrochloride alone once a day for at least 8 consecutive days.
8. The method of claim 7 , wherein the method is more effective in treating major depressive disorder than orally administering 90 mg of dextromethorphan hydrobromide alone once a day for at least 8 consecutive days.
9. The method of claim 7 , wherein about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide are orally administered once a day to the human being.
10. The method of claim 7 , wherein about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide are orally administered once a day to the human being for at least 14 consecutive days.
11. The method of claim 7 , wherein about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide are orally administered once a day to the human being for at least 30 consecutive days.
12. The method of claim 7 , wherein the combination is orally administered once a day to the human being for at least 30 days.
13. A method of treating major depressive disorder, comprising orally administering a combination of bupropion and dextromethorphan once a day or twice a day to a human being in need thereof for at least 8 consecutive days, wherein the combination comprises:
about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide twice a day;
about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide once a day; or
an amount of a bupropion in the free base form or a salt form and an amount of dextromethorphan in the free base form or a salt form once a day or twice a day that provides, to the human being, about the same AUC 0-24 of bupropion and about the same AUC 0-24 of dextromethorphan as administering: about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide twice a day;
wherein the combination is orally administered in a single dosage form comprising the bupropion and the dextromethorphan as the only therapeutically active compounds, which provides immediate release of dextromethorphan and sustained release of bupropion; and
wherein the method is more effective in treating major depressive disorder than orally administering 105 mg of bupropion hydrochloride alone twice a day for at least 8 consecutive days.
14. The method of claim 13 , wherein the method is more effective in treating major depressive disorder than orally administering 45 mg of the dextromethorphan alone twice a day for at least 8 consecutive days.
15. The method of claim 13 , wherein the combination is orally administered twice a day to the human being.
16. The method of claim 13 , wherein the combination is orally administered once a day to the human being.
17. The method of claim 13 , wherein the combination is orally administered for at least 14 consecutive days.
18. The method of claim 13 , wherein the combination is orally administered for at least 30 consecutive days.
19. The method of claim 1 , wherein the dosage form comprises a pharmaceutically acceptable excipient.
20. The method of claim 7 , wherein the dosage form comprises a pharmaceutically acceptable excipient.
21. The method of claim 13 , wherein the dosage form comprises a pharmaceutically acceptable excipient.
22. The method of claim 1 , wherein the human being has treatment resistant depression.
23. The method of claim 7 , wherein the human being has treatment resistant depression.
24. The method of claim 13 , wherein the human being has treatment resistant depression.
25. The method of claim 1 , wherein the human being is an adult.
26. The method of claim 7 , wherein the human being is an adult.
27. The method of claim 13 , wherein the human being is an adult.